Skip to main content


ASH 2018 CLL Research and Updates

December 20, 2018

December 1-4 marked the annual ASH Annual Meeting and Exposition. Leading experts convened in San Diego, CA to address the latest news and research updates in chronic lymphocytic leukemia.




Real-World Experiences of CAR-T Therapy in Patients With Relapsed, Refractory Large B-Cell Lymphoma

Loretta J Nastoupil, MD, The University of Texas MD Anderson Cancer Center, considers the findings of the ZUMA-1 study and their comparability to real-world outcomes in patients with large B-cell lymphoma receiving CAR-T therapy.

Listen to the podcast


TLS Prophylaxis, Management in Patients With Previously-Treated CLL

Chadi Nabhan, MD, Cardinal Health, discusses adverse events, patterns of TLS prophylaxis and management, and dosing patterns in patients with CLL treated in community and academic settings.

Listen to the podcast


Institutional Resource Utilization After CAR-T Infusion for Hematologic Malignancies

Gunjan L Shah, MD, MS, Memorial Sloan Kettering Cancer Center, explains how increasing use of CAR-T therapy can create challenges in institutional resource capacity and how identifying these resources will allow for better care delivery and allocation of funds.

Listen to the podcast


Failure on Daratumumab-Based Therapy in Multiple Myeloma: A Pooled Analysis of PREAMBLE, McKesson's EMR

Ravi Vij, MD, MBA, discusses real-world findings related to patients with relapsed or refractory multiple myelomaafter daratumumab treatment from a pooled dataanalysis, PREAMBLE, and the McKesson electronic medical record database.

Listen to the podcast


Is CAR-T Therapy Comparable to Past Innovative Therapies in Regard to Health Outcomes, Cost-Effectiveness?

James Baumgardner, PhD, discusses how CAR-Ttherapy displays favorable gains in health outcomes and competitive cost-effectiveness when compared with pastinnovative cancer treatments.

Listen to the podcast


Finding the Optimal Treatment of IDH2-Mutated AML: Results of the BEAT AML Master Trial

Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, discusses the larger implications of the BEAT AML Master Trial, which examined a novel treatment option for previously untreated IDH2-mutant AML.

Listen to the podcast





Understanding the Factors that Influence Treatment Decision-Making in Patients With CLL

Matthew S Davids, MD, MMSc, discusses a presentation at the ASH Annual Meeting and Exposition about the CLL Society’s exploration of how patients with CLL make therapy decisions. 

Read More

Expert Insights


Expert Roundtable: Lessons From ASH for Optimizing CLL Treatment

Jeff Sharman, MD, Anthony Mato, MD, MSCE, and Chaitra Ujjani, MD, converse at the ASH Annual Meeting and Exposition about the findings of an interim analysis from the prospective informCLL real-world registry and optimizing CLL treatment in real-world practice.

Listen to the conversation



Novel CLL Scoring System Helps Predict Risk of Atrial Fibrillation

A new scoring system model may be a valid tool for identifying patients with CLL at higher risk of developing atrial fibrillation, including those treated with a targeted therapy. 

Read More


Prognostic Testing, Treatment Approaches in Patients With CLL

A study shed light on a “considerable lack” of prognostic marker testing among patients with CLL in the modern era. 

Read More


Treatment Decision-Making in CLL: The Patient Perspective

A survey showed that most patients with CLL want to be involved in therapy decisions and that gender, age, and therapy status influence decision-making. 

Read More

Back to Top